Case Study

High-fiber Diet for Treating Chronic Diarrhea in Dogs

Metabolon helps identify functional metabolomic changes in the gut microbiome in dogs with chronic diarrhea fed a high-fiber diet.

Metabolon’s metabolomics platform helped identify metabolic changes that occurred when dogs with diarrhea were fed a high-fiber diet. These insights are critical in helping drive innovation towards more targeted, efficacious solutions for dogs with chronic diarrhea, improving the quality of life for dogs and their owners.

Biomarkers By Metabolon

Metabolon’s metabolomics platform helped identify metabolic changes that occurred when dogs with diarrhea were fed a high-fiber diet. These insights are critical in helping drive innovation towards more targeted, efficacious solutions for dogs with chronic diarrhea, improving the quality of life for dogs and their owners.

This study1 utilized metabolomics to identify functional metabolomic changes in response to a nutritional intervention in dogs with chronic large bowel diarrhea.

Chronic large bowel diarrhea is common in dogs, significantly impacting the quality of life for both dog and owner and representing one of the top medical reasons dogs visit primary-care veterinary clinics.2 Nutritional interventions are considered preferred treatments since most cases of chronic diarrhea occur concurrently with intestinal dysbiosis or an imbalance in the gut microbiota. Specific dietary fiber blends are often utilized as they selectively nourish beneficial colonic bacteria and provide vital substrates necessary to restore healthy intestinal microbial growth, and, ultimately, reduce clinical signs.

Previous studies3-5 demonstrated this novel fiber blend shifted the gut microbiome of dogs with chronic diarrhea towards a healthier state. Specifically, the fiber blend improved stool quality, increased fecal saccharolytic products, and increased fecal antioxidant and anti-inflammatory metabolites. Additionally, the microbiome diversity in treated dogs with chronic enteritis/gastroenteritis became more like that of healthy dogs. A companion analysis of the current study reported rapidly improved stool consistency, resolution of clinical signs, and improved stooling behaviors and quality of life in dogs with chronic large bowel diarrhea.1, 5

This recent publication helps characterize the metabolites and biochemical pathways underlying treatment efficacy in dogs with chronic large bowel diarrhea. When study dogs were fed the novel fiber blend, gut metabolism shifted from predominantly proteolytic to saccharolytic fermentative state, a shift considered beneficial for gut health. Increases in bioavailable plant-derived indole and phenolics as well as modulation of gut inflammation were also reported. Collectively, the functional metabolic changes are indicative of a shift to improved gut function and a possible pathophysiological mechanism related to improved clinical signs of diarrhea.

The Challenge

The efficacy of nutritional interventions in dogs with chronic diarrhea is well documented, with many studies demonstrating beneficial shifts in the gut microbiome composition. Quantifying fecal firmness, pH, moisture, and ash content allows evaluation of stool consistency and characteristics. Fecal microbiome analysis captures a snapshot of the gut microbiome, provides insight to the amount and type of microbes present. As valuable as these methods are, however, they don’t tease apart the functional metabolic changes that occur because of the nutritional intervention.

Metabolon Insight

By elucidating the metabolomic changes or signature differences, our Global Discovery Panel helped drive innovation of more targeted, efficacious solutions for dogs with chronic large bowel diarrhea. Metabolon’s unmatched chemical library and biological interpretation expertise made it possible to identify, track, and map metabolites across 70 major biochemical pathways providing the most comprehensive coverage of the gut metabolome.

The statistical analysis, interpretation, and interactive visualization tools allow Metabolon to deliver the most comprehensive and mechanistic view of the underlying biology of your subject with a complete, accurate, and reliable interpretation that delivers knowledge, not just data.

The Solution

The Metabolon Discovery Global Platform used untargeted metabolomics profiling on fecal and serum study samples to help characterize the specific microbiome and biochemical contributions that led to improvements in clinical signs of diarrhea following treatment with the novel fiber blend.

Figure 1. Fecal ammonia concentrations, as an indicator of the impact of dietary intervention on fermentative metabolism.

The Outcome

While improved clinical signs and compositional changes to the fecal microbiome were notable, Metabolon’s metabolomic analysis also allowed for the identification of complex fecal and circulating biochemical differences between treatment groups which could be used as biomarkers of treatment.

Metabolomic analysis revealed that when dogs with chronic diarrhea were fed the novel fiber blend, gut metabolism shifted from predominantly proteolytic to saccharolytic fermentative state, indicating that the high-fiber intervention altered the protein-derived substrate availability for the colonic microbiota, resulting in a decreased catabolic signature. This shift is generally considered to be beneficial for gut health. Increases in bioavailable plant-derived indole and phenolics as well as modulation of gut inflammation (via endocannabinoid, polyunsaturated fatty acid, and sphingolipid pathways), were also reported. Collectively, the functional metabolic changes are indicative of a shift to improved gut function and a possible pathophysiological mechanism related to improved clinical signs of diarrhea.

References

1. Fritsch DA, Jackson MI, Wernimont SM, Feld GK, MacLeay JM, Brejda JJ, et al. Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res. 2022;18(1):245.

2. Kim E, Choe C, Yoo JG, Oh SI, Jung Y, Cho A, et al. Major medical causes by breed and life stage for dogs presented at veterinary clinics in the Republic of Korea: a survey of electronic medical records. PeerJ. 2018;6:e5161.

3. Jackson MI, Jewell DE. Balance of saccharolysis and proteolysis underpins improvements in stool quality induced by adding a fiber bundle containing bound polyphenols to either hydrolyzed meat or grain-rich foods. Gut Microbes. 2019;10(3):298-320.

 

4. Wernimont SM, Paetau-Robinson I, Jackson MI, Gross KL. Bacterial Metabolism of Polyphenol-rich Fibers in a True Carnivore, Felis catus. The FASEB Journal. 2019;33(S1):723.3-.3.

5. Fritsch DA, Wernimont SM, Jackson MI, MacLeay JM, Gross KL. A prospective multicenter study of the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res. 2022;18(1):244.

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.